Nursing Diagnosing (PDAR)

DRUG STUDY
PATIENT PROFILE
DOB: 05/30/85
Age: 29
Sex: Male
Citizenship: Filipino
Civil Status:
Single
Service: Internal Medicine
Doctors Complete Drug Order:
Amlodipine besylate (Norvasc 10 mg/tablet)
1tab orally once daily
Generic Name: Amlodipine besylate

Name: Norvasc
Brand
Category:
HAMS
Regular Drug
LASA
Therapeutic Category: Calcium Channel Blocker/
Calcium Ion Antagonist
Uses: NORVASC is indicated for the treatment of hypertension, to lower blood pressure.
Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events,
primarily strokes and myocardial infarctions. These benefits have been seen in controlled
trials of antihypertensive drugs from a wide variety of pharmacologic classes including
NORVASC.
Control of high blood pressure should be part of comprehensive cardiovascular risk
management, including, as appropriate, lipid control, diabetes management, antithrombotic
therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require
more than one drug to achieve blood pressure goals. For specific advice on goals and
management, see published guidelines, such as those of the National High Blood Pressure
Education Program's Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different
mechanisms of action, have been shown in randomized controlled trials to reduce
cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure
reduction, and not some other pharmacologic property of the drugs, that is largely
responsible for those benefits. The largest and most consistent cardiovascular outcome
benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and
cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute
risk increase per mmHg is greater at higher blood pressures, so that even modest reductions
of severe hypertension can provide substantial benefit. Relative risk reduction from blood
pressure reduction is similar across populations with varying absolute risk, so the absolute
benefit is greater in patients who are at higher risk independent of their hypertension (for
example, patients with diabetes or hyperlipidemia), and such patients would be expected to
benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black
patients, and many antihypertensive drugs have additional approved indications and effects
(e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide
selection of therapy.
NORVASC may be used alone or in combination with other antihypertensive agents.
DRUG STUDY
Pertinent History and PE:

One month PTA, patient noted onset of
numbness of both hands that occurred during
performance of activities like driving and
typing. Condition tolerated. No other signs and
symptoms noted. Two days PTA, patient had
onset of jaw fitness with no triggering factors
and with spontaneous resolution. Persistence
of signs and symptoms prompted consult and
subsequent
admission.
Laboratory/ Diagnostic Procedure related
to
Drug
Therapy:
ESR: 13 mm/hr increased
Pharmacokinetics: After oral administration of therapeutic doses of NORVASC,

absorption produces peak plasma concentrations between 6 and 12 hours. Absolute
bioavailability has been estimated to be between 64 and 90%. The bioavailability of
NORVASC is not altered by the presence of food.
Amlodipine is extensively (about 90%) converted to inactive metabolites via hepatic
metabolism with 10% of the parent compound and 60% of the metabolites excreted
in the urine. Ex vivo studies have shown that approximately 93% of the circulating
drug is bound to plasma proteins in hypertensive patients. Elimination from the
plasma is biphasic with a terminal elimination half-life of about 3050 hours. Steadystate plasma levels of amlodipine are reached after 7 to 8 days of consecutive daily
dosing.
The pharmacokinetics of amlodipine are not significantly influenced by renal
impairment. Patients with renal failure may therefore receive the usual initial dose.
Elderly patients and patients with hepatic insufficiency have decreased clearance of
amlodipine with a resulting increase in AUC of approximately 4060%, and a lower
initial dose may be required. A similar increase in AUC was observed in patients with
moderate to severe heart failure.
Pediatric Patients: Sixty-two hypertensive patients aged 6 to 17 years received doses
of NORVASC between 1.25 mg and 20 mg. Weight adjusted clearance and volume of
distribution were similar to values in adults.
Contraindications: Contraindicated with allergy to amlodipine
Special Concerns/ Warnings/ Precautions: Hypotension: Symptomatic hypotension is
possible, particularly in patients with severe aortic stenosis. Because of the gradual onset of
action, acute hypotension is unlikely.
Increased Angina or Myocardial Infarction: Worsening angina and acute myocardial
infarction can develop after starting or increasing the dose of NORVASC, particularly in
patients with severe obstructive coronary artery disease.
Patients with Hepatic Failure: Because NORVASC is extensively metabolized by the liver
and the plasma elimination half-life (t ) is 56 hours in patients with impaired hepatic
DRUG STUDY
function, titrate slowly when administering NORVASC to patients with severe hepatic
impairment.
Side Effects:
Cardiovascular: arrhythmia (including ventricular tachycardia and atrial
fibrillation), bradycardia, chest pain, peripheral ischemia, syncope, tachycardia, vasculitis.

Central
and
Peripheral
Nervous
peripheral, paresthesia, tremor, vertigo.
Gastrointestinal: anorexia,
vomiting, gingival hyperplasia.
System: hypoesthesia,
constipation, dysphagia,
neuropathy
diarrhea, flatulence,pancreatitis,
General: allergic reaction, asthenia,1 back pain, hot flushes, malaise, pain, rigors, weight
gain, weight decrease.
Musculoskeletal System: arthralgia, arthrosis, muscle cramps,1 myalgia.
Psychiatric: sexual dysfunction (male1 and female), insomnia, nervousness, depression,
abnormal dreams, anxiety, depersonalization.
Respiratory System: dyspnea,1 epistaxis.
Skin
and
Appendages: angioedema,
erythematous, rash maculopapular.
erythema
multiforme, pruritus,1rash,1 rash
Special Senses: abnormal vision, conjunctivitis, diplopia, eye pain, tinnitus.

Urinary System: micturition frequency, micturition disorder, nocturia.
Autonomic Nervous System: dry mouth, sweating increased.
Metabolic and Nutritional: hyperglycemia, thirst.
Hemopoietic: leukopenia, purpura, thrombocytopenia
DRUG STUDY
Food and Drug Interactions: Cimetidine, Grapefruit Juice, Magnesium and Aluminum
Hydroxide Antacid, Sildenafil, Atorvastatin, Simvastatin, Digoxin, Ethanol (Alcohol),
Warfarin, CYP3A4 Inhibitors, CYP3A4 Inducer, Cyclosporine
Overdose Management: Overdosage might be expected to cause excessive peripheral

vasodilation with marked hypotension and possibly a reflex tachycardia. In humans,
experience with intentional overdosage of NORVASC is limited.
Single oral doses of amlodipine maleate equivalent to 40 mg amlodipine/kg and 100 mg
amlodipine/kg in mice and rats, respectively, caused deaths. Single oral amlodipine maleate
doses equivalent to 4 or more mg amlodipine/kg or higher in dogs (11 or more times the
maximum recommended human dose on a mg/m basis) caused a marked peripheral
vasodilation and hypotension.
If massive overdose should occur, initiate active cardiac and respiratory monitoring. Frequent
blood pressure measurements are essential. Should hypotension occur, provide
cardiovascular support including elevation of the extremities and the judicious administration
of fluids. If hypotension remains unresponsive to these conservative measures, consider
administration of vasopressors (such as phenylephrine) with attention to circulating volume
and urine output. As NORVASC is highly protein bound, hemodialysis is not likely to be of
benefit.

Nursing Diagnosing (PDAR)

Uploaded by

Copyright:

Available Formats

Nursing Diagnosing (PDAR)

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Nursing Diagnosing (PDAR)

Uploaded by

Copyright:

Available Formats

DRUG STUDY

Generic Name: Amlodipine besylate

Pertinent History and PE:

ESR: 13 mm/hr increased

Pharmacokinetics: After oral administration of therapeutic doses of NORVASC,

fibrillation), bradycardia, chest pain, peripheral ischemia, syncope, tachycardia, vasculitis.

multiforme, pruritus,1rash,1 rash

Special Senses: abnormal vision, conjunctivitis, diplopia, eye pain, tinnitus.

Overdose Management: Overdosage might be expected to cause excessive peripheral

You might also like